Managed Care Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Managed Care Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Karolinska University Hospital
Selective D2 -like receptor agonist shows promise as radioligand
August 16th, 2005
A synthetic dopamine D2 -like receptor agonist shows promise as a radioligand for imaging the D2 receptor (D2 R). Scientists in Sweden conducted a "preliminary positron emission tomography (PET) evaluation of a dopamine D2 -like receptor agonist, (R)-2-11CH3 O-N-n-propylnorapomorphine ([11C]MNPA), as a potential new radioligand for in vivo imaging of the high-affinity state" of D2 R. "MNPA is a selective D2 -like receptor agonist with a high affinity (Ki =0.17 nM)," explained S.J. Finnema and coauthors at Karolinska...
Source: Managed Care Business Week (2005-08-16)
|
